|
(Health-NewsWire.Net, February 17, 2021 ) The report "Embolotherapy Market by Product (Embolic Agents (Microspheres, Detachable Coils, Pushable Coils), Guidewires), Disease (Oncology, Aneurysm, Peripheral Vascular), Procedure, End User (Hospitals, Clinics, ASC, Academia) - Global Forecast to 2024", is projected to reach USD 4.9 billion by 2024 from USD 3.3 billion in 2019, at a CAGR of 8.1% from 2019 to 2024
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=185897830
The growth of the embolotherapy market is mainly attributed to factors such as the growth in the target patient population, rising preference for minimally invasive procedures, technological advancements in embolotherapy devices, and favorable reimbursement scenario.
The embolic agents segment accounted for the largest share of the embolotherapy market, by product, in 2019
Based on product, the embolotherapy market is segmented into embolic agents (embolic coils, embolic plug systems, liquid embolic agents, microspheres, and detachable balloons) and support devices (microcatheters and guidewires). Microspheres accounted for the largest share of the embolotherapy market in 2018. Market growth in this segment is attributed to the surge in the prevalence of hepatocellular carcinoma (microspheres are widely used to treat this disease), coupled with favorable reimbursement criteria in developed economies.
The cancer segment is projected to hold the largest share of the market by disease indication during the forecast period of 2019 to 2024
By disease indication, the embolotherapy market is classified into cancer, peripheral vascular diseases, neurological diseases, urological & nephrological disorders, and gastrointestinal disorders. The cancer segment held the largest share of the embolotherapy market in 2019. The rising preference for minimally invasive procedures, expansion of the target patient population, growing public-private funding & government support for cancer research, and technological advancements in the field of microspheres are driving the growth of this segment.
Hospitals and clinics were the key end users in the embolotherapy market
On the basis of end users, the embolotherapy market is segmented into hospitals and clinics, ambulatory surgery centers (ASCs), and other end users. In 2018, the hospital and clinics segment held the largest share of the embolotherapy market. The growing adoption of minimally invasive surgical procedures (including vascular, urological, and neurological procedures), increasing purchasing power of major healthcare providers across developed countries (owing to the consolidation of healthcare providers), and the greater availability of reimbursements for target procedures in the US and major European countries are the major factors that are expected to drive the demand for embolization devices in hospitals and clinics.
Get a Sample report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=185897830
North America is expected to accounted for the largest share of the Embolotherapy market in 2019
The embolotherapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is projected to hold the largest share of the regional market for embolotherapy products in 2019. The growing geriatric population, the increasing number of ASCs, and a growing preference for minimally invasive surgeries have resulted in the increasing adoption of embolotherapy procedures in the country.
The major players in the market include Boston Scientific Corporation (US), Merit Medical Systems (US), Terumo Corporation (Japan), Medtronic plc (Ireland), Johnson & Johnson (US), Stryker Corporation (US), BTG plc (UK), Penumbra, Inc. (US), Cook Medical (US), Abbott Laboratories (US), Acandis GmbH (Germany), BALT Extrusion (France), Sirtex Medical Limited (Australia), Kaneka Corporation (Japan), and Meril Life Sciences Pvt. Ltd. (India) among others.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
|
